Baxter Halts Shipments of Novum LVP After Reports of Injuries and Deaths Linked to Device Safety Issues
Reuters
Nov 03
Baxter Halts Shipments of Novum LVP After Reports of Injuries and Deaths Linked to Device Safety Issues
Baxter International Inc. has announced significant safety concerns with its Novum Large Volume Pump (LVP) medical device, following reports of inaccurate infusion rates leading to both under infusion and over infusion. The company disclosed that it has received 79 reports of serious injuries and two patient deaths related to the device. On July 31, 2025, Baxter announced a voluntary and temporary pause on shipments and planned installations of the Novum LVP, citing issues identified through quality monitoring systems and customer feedback. Despite earlier warnings and corrective instructions to hospitals, Baxter is currently unable to commit to a timeline for resuming shipments. Following the announcement, the company's stock price dropped by more than 22%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baxter International Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1095830) on November 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.